iShares MSCI ACWI ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI ACWI ETF trades at $161.62, while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | FLNA | |
|---|---|---|
52-Week High | $161.44 | $4.64 |
52-Week Low | $132.04 | $0.87 |
Market Cap | — | $47.75M |
Sector | — | Health |
Enterprise Value | — | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.72, up 0.38% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The ETF's forward P/E of 15.5x, as of Seeking Alpha on 2026-07-07, suggests reasonable valuation amid robust earnings growth, with Information Technology now comprising 32% of holdings. A dividend of $1.01 is scheduled for June 2026.
Outlook remains positive due to strong EPS growth and institutional interest, though overbought RSI levels near 74.95 signal caution. Risks include market volatility from AI-driven inflows and potential sector concentration, but analyst sentiment supports a buy rating for long-term global equity exposure.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Trailing returns across standard periods
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →